[1] [1] DERYNCK R, TURLEY S J, AKHURST R J. TGFβ biology in cancer progression and immunotherapy ［J］. Nature Reviews Clinical Oncology, 2021, 18(1): 9-34.

[2] [2] ZHAO B M. Inhibition of transforming growth factor-beta1-induced signaling and epithelial-to-mesenchymal transition by the Smad-binding peptide aptamer Trx-SARA. ［J］. Molecular Biology of the Cell, 2006, 17(9): 3819-3831.

[3] [3] JANJI B, MELCHIOR C, GOUON V, et al. Autocrine TGF-β-regulated expression of adhesion receptors and integrin-linked kinase in HT-144 melanoma cells correlates with their metastatic phenotype ［J］. International Journal of Cancer, 2015, 83(2): 255-262.

[4] [4] WILLIS B C, BOROK Z. TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease ［J］. AJP Lung Cellular and Molecular Physiology, 293(3): L525-L534.

[5] [5] DOOLEY S, TEN DIJKE P. TGF-beta in progression of liver disease ［J］. Cell and Tissue Research, 2012, 347(1): 245-256.

[6] [6] LO C M, WANG H B, DEMBO M, et al. Cell movement is guided by the rigidity of the substrate ［J］. Biophysical Journal, 2000, 79(1): 144-152.

[7] [7] QIN X, LYU X, LI P, et al. Matrix stiffness modulates ILK-mediated YAP activation to control the drug resistance of breast cancer cells ［J］. Biochimica et Biophysica Acta-molecular Basis of Disease, 2020, 1866(3): 165625.

[8] [8] SUN D Y, WU J Q, HE Z H, et al. Cancer-associated fibroblast regulate proliferation and migration of prostate cancer cells through TGF-beta signaling pathway ［J］. Life Sciences, 2019, 235: 116791.

[9] [9] GOULET C R, POULIOT F. TGF-beta signaling in the tumor microenvironment ［J］. Tumor Microenvironment, 2021, 1270: 89-105.

[10] [10] SAYERS E W, AGARWALA R, BOLTON E E, et al. Database resources of the National Center for Biotechnology Information ［J］. Nucleic Acids Research, 2018, 47(D1): D8-D13.

[11] [11] WILKINS M R, GASTEIGER E, BAIROCH A, et al. Protein identification and analysis tools in the ExPASy server ［J］. Methods in Molecular Biology, 1999, 112: 531-552.

[12] [12] PETERSEN T N, BRUNAK S, VON HEIJNE G, et al. SignalP 4.0: discriminating signal peptides from transmembrane regions ［J］. Nature Methods, 2011, 8(10): 785-786.

[13] [13] CHEN Y, YU P, LUO J, et al. Secreted protein prediction system combining CJ-SPHMM, TMHMM, and PSORT ［J］. Mammalian Genome, 2003, 14(12): 859-865.

[14] [14] GEOURJON C, DELEAGE G. SOPMA: significant improvements in protein secondary structure prediction by consensus prediction from multiple alignments ［J］. Computer Application in the Biosciences, 1995, 11(6): 681-684.

[15] [15] ZHANG T, JIA L F, CHEN Y, et al. Cloning, expression and bioinformatics analysis of cathepsin B of Echinococcus granulosus［J］. Europe PMC, 2014, 26(6): 642-647.

[16] [16] GUPTA R, BRUNAK S. Prediction of glycosylation across the human proteome and the correlation to protein function ［J］. Pacific Symposium on Biocomputing, 2002, 7(3): 310-322.

[17] [17] BLOM N, GAMMELTOFT S, BRUNAK S. Sequence and structure-based prediction of eukaryotic protein phosphorylation sites ［J］. Journal of Molecular Biology, 1999, 294(5): 1351-1362.

[18] [18] TANG Z, LI C, KANG B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses ［J］. Nucleic Acids Research, 2017, 45(W1): W98-W102.

[19] [19] PINHO S S, REIS C A. Glycosylation in cancer: mechanisms and clinical implications ［J］. Nature Reviews Cancer, 2015, 15(9): 540-555.

[20] [20] RODRIGUES J G, BLAMANA M, MACEDOJ A, et al. Glycosylation in cancer: selected roles in tumour progression, immune modulation and metastasis ［J］. Cellular Immunology, 2018, 333: 46-57.

[21] [21] TSUI P, HIGAZI D R, WU Y, et al. The TGF-β inhibitory activity of antibody 37E1B5 depends on its H-CDR2 glycan ［J］. Mabs-Austin, 2017, 9(1): 104-113.

[22] [22] HAJBA L, SZEKRENYES A, BORZA B, et al. On the glycosylation aspects of biosimilarity ［J］. Drug Discovery Today, 2018, 23(3): 616-625.

[23] [23] KINGSLEY D M. The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms ［J］. Genes & Development, 1994, 8(2): 133-146.

[24] [24] OOSHIMA A, PARK J, KIM S J. Phosphorylation status at Smad3 linker region modulates transforming growth factor-beta-induced epithelial-mesenchymal transition and cancer progression ［J］. Cancer Science, 2019, 110(2): 481-488.

[25] [25] PETITI J, SOSA L, PICECH F, et al. Trastuzumab inhibits pituitary tumor growth modulating the TGFB/Smad2/3 pathway ［J］. Endocrine-Related Cancer, 2018, 25(10): 837-852.

[26] [26] MARWITZ S, BALLESTEROS-MERINO C, JENSEN S M, et al. Phosphorylation of SMAD3 in immune cells predicts survival of patients with early stage non-small cell lung cancer ［J］. Journal for Immunotherapy of Cancer, 2021, 9(2): e001469.

[27] [27] ISHIMOTO T, MIYAKE K, NANDI T, et al. Activation of transforming growth factor beta 1 signaling in gastric cancer-associated fibroblasts increases their motility, via expression of rhomboid 5 homolog 2, and ability to induce invasiveness of gastric cancer cells ［J］. Gastroenterology, 2017, 153(1): 191-204.

[28] [28] CHEN Y, DI C, ZHANG X, et al. Transforming growth factor beta signaling pathway: a promising therapeutic target for cancer ［J］. Journal Cellular Physiology, 2020, 235(3): 1903-1914.

[29] [29] CHEN Y P, WANG Y Q, LYU J W, et al. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy ［J］. Annals of Oncology, 2018, 30(1): 68-75.

[30] [30] ZHANG Y, CHEN J, ZHOU N, et al. FUBP1 mediates the growth and metastasis through TGF beta/Smad signaling in pancreatic adenocarcinoma ［J］. International Journal of Molecular Medicine, 2021, 47(5): 66.